Novo Nordisk A/S Chief Executive Officer Mike Doustdar talks about the company's performance as its popular Wegovy weight-loss pill disappointed investors with sales that failed to live up to the hype. "We are not right now discussing further discounts," Doustdar tells Bloomberg's Francine Lacqua. (Source: Bloomberg)
Novo Nordisk A/S Chief Executive Officer Mike Doustdar talks about the company's performance as its popular Wegovy weight-loss pill disappointed investors with sales that failed to live up to the hype. "We are not right now discussing further discounts," Doustdar tells Bloomberg's Francine Lacqua. (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/2e156484489ad522f21a87574ae06c2b10016f74" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Novo Not Discussing Further Pill Discounts, CEO Says"></iframe>
